File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Serum level of DKK1 as a marker for predicting tumor recurrence of hepatocellular carcinoma

TitleSerum level of DKK1 as a marker for predicting tumor recurrence of hepatocellular carcinoma
Authors
Issue Date2010
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://www.aacrmeetingabstracts.org/
Citation
The 101st Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC., 17-21 April 2010. In AACR Meeting Abstracts, 2010 How to Cite?
AbstractDickkopf-1 (DKK1), an inhibitor of Wnt/beta-catenin signaling pathway, is upregulated in various cancers including HCC. However, the clinical significance of serum DKK1 in hepatocellullar carcinoma (HCC) remains to be determined. The objective of this study was to investigate the clinical significance of DKK1 and its prognostic value in predicting survival and tumor recurrence in human HCC. Two independent cohorts with 217 and 100 pairs of tumors and corresponding nontumor livers were employed for microarray analysis and real time-quantitative PCR (qPCR), respectively, to investigate the DKK1 transcript levels in human HCC samples. The serum levels of DKK1 were determined in 50 patients with early HCC, 50 patients with advanced HCC, 50 patients with cirrhosis, 50 hepatitis B virus (HBV) carriers, and 30 HCC patients after liver resection, using sandwich ELISA system. Transcript level of DKK1 in the human HCCs was found to be significantly upregulated as compared with the corresponding nontumorous livers in both microarray (P < 0.001) and qPCR cohorts (P < 0.001). Increased expression of DKK1 was associated with advanced tumor stage (P < 0.001), venous infiltration (P < 0.001), high serum alpha-fetoprotein (AFP) level (P < 0.001). Higher level of DKK1 correlated with both poorer overall survival (P = 0.016) and tumor recurrence (P = 0.014). On the other hand, the serum DKK1 level in the group of HBV carriers without HCC (as control) was not significantly different from that of the cirrhosis group (P = 0.086). In contrast, the serum DKK1 level was significantly higher in patients with early HCC (P < 0.001) and advanced HCC (P < 0.001), as compared with the HBV carrier group. Furthermore, the serum DKK1 level in patients after liver resection was significantly reduced (P < 0.001). Higher serum DKK1 level was associated with tumor recurrence (P = 0.046). To conclude, our data have demonstrated that tissue and serum DKK1 levels were significantly and progressively elevated during HCC formation and progression. DKK1 has prognostic role in predicting overall survival and disease-free survival of HCC patients, and serum DKK1 is a potential biomarker for predicting tumor recurrence.
DescriptionPoster Session 31 - Molecular Diagnostics and Therapeutic Targets 2: abstract no. 1779
Persistent Identifierhttp://hdl.handle.net/10722/126688
ISSN

 

DC FieldValueLanguage
dc.contributor.authorTung, EKKen_HK
dc.contributor.authorMak, CKMen_HK
dc.contributor.authorLee, JMFen_HK
dc.contributor.authorLi, JJen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorLuk, JMCen_HK
dc.contributor.authorNg, IOLen_HK
dc.date.accessioned2010-10-31T12:42:47Z-
dc.date.available2010-10-31T12:42:47Z-
dc.date.issued2010en_HK
dc.identifier.citationThe 101st Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC., 17-21 April 2010. In AACR Meeting Abstracts, 2010en_HK
dc.identifier.issn1948-3279-
dc.identifier.urihttp://hdl.handle.net/10722/126688-
dc.descriptionPoster Session 31 - Molecular Diagnostics and Therapeutic Targets 2: abstract no. 1779-
dc.description.abstractDickkopf-1 (DKK1), an inhibitor of Wnt/beta-catenin signaling pathway, is upregulated in various cancers including HCC. However, the clinical significance of serum DKK1 in hepatocellullar carcinoma (HCC) remains to be determined. The objective of this study was to investigate the clinical significance of DKK1 and its prognostic value in predicting survival and tumor recurrence in human HCC. Two independent cohorts with 217 and 100 pairs of tumors and corresponding nontumor livers were employed for microarray analysis and real time-quantitative PCR (qPCR), respectively, to investigate the DKK1 transcript levels in human HCC samples. The serum levels of DKK1 were determined in 50 patients with early HCC, 50 patients with advanced HCC, 50 patients with cirrhosis, 50 hepatitis B virus (HBV) carriers, and 30 HCC patients after liver resection, using sandwich ELISA system. Transcript level of DKK1 in the human HCCs was found to be significantly upregulated as compared with the corresponding nontumorous livers in both microarray (P < 0.001) and qPCR cohorts (P < 0.001). Increased expression of DKK1 was associated with advanced tumor stage (P < 0.001), venous infiltration (P < 0.001), high serum alpha-fetoprotein (AFP) level (P < 0.001). Higher level of DKK1 correlated with both poorer overall survival (P = 0.016) and tumor recurrence (P = 0.014). On the other hand, the serum DKK1 level in the group of HBV carriers without HCC (as control) was not significantly different from that of the cirrhosis group (P = 0.086). In contrast, the serum DKK1 level was significantly higher in patients with early HCC (P < 0.001) and advanced HCC (P < 0.001), as compared with the HBV carrier group. Furthermore, the serum DKK1 level in patients after liver resection was significantly reduced (P < 0.001). Higher serum DKK1 level was associated with tumor recurrence (P = 0.046). To conclude, our data have demonstrated that tissue and serum DKK1 levels were significantly and progressively elevated during HCC formation and progression. DKK1 has prognostic role in predicting overall survival and disease-free survival of HCC patients, and serum DKK1 is a potential biomarker for predicting tumor recurrence.-
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://www.aacrmeetingabstracts.org/-
dc.relation.ispartofAACR Meeting Abstracts-
dc.titleSerum level of DKK1 as a marker for predicting tumor recurrence of hepatocellular carcinomaen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailTung, EKK: edmund@pathology.hku.hken_HK
dc.identifier.emailMak, CKM: carmenmak@gmail.comen_HK
dc.identifier.emailLee, JMF: joyce@pathology.hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailLuk, JMC: jmluk@hkucc.hku.hken_HK
dc.identifier.emailNg, IOL: iolng@hkucc.hku.hken_HK
dc.identifier.hkuros175538en_HK
dc.description.otherThe 101st Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC., 17-21 April 2010. In AACR Meeting Abstracts, 2010-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats